Glaukos Q2 record net sales $124.1M (+30% YoY); raises FY 2025 guidance to $480-486M

GLAUKOS Corp

2025-Q2 EPS reported -$0.66 revenue$230,784,000

Record net sales $124.1M, up 30% YoY; glaucoma sales $103.5M (+36%), U.S. glaucoma $72.3M (+45%).
Net loss narrowed to $19.7M ($0.34 per share) from $50.5M ($1.00); non-GAAP loss $13.6M ($0.24).
Gross margin ~78%, non-GAAP ~83%; cash & investments $278.6M, zero debt.
Raised 2025 net sales guidance to $480-486M (prior $475-485M); management cites sustained growth acceleration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.